Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ALBANY MOLECULAR RESEARCH INC (AMRI)
|
Add to portfolio |
|
|
|
| Price: |
$21.74
| | Metrics |
| OS: |
42.9
|
M
| |
-19
|
% ROE
|
| Market cap: |
$933
|
M
| |
-1
|
% ROIC
|
|
Net debt:
|
$606
|
M
| |
10.0
|
x Debt/EBITDA
|
|
EV:
|
$1.54
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$60.6
|
M
| |
25.4
|
x EV/EBITDA
|
|
EBIT
|
($8.0)
|
M
| |
|
|
| EPS |
($1.46)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
| Revenues | 570.5 | 402.4 | 276.6 | 246.6 | 226.7 | 207.6 | 198.1 | 196.4 |
| Revenue growth | 41.8% | 45.5% | 12.2% | 8.8% | 9.2% | 4.8% | 0.8% | -14.3% |
| Cost of goods sold | 437.6 | 295.5 | 209.2 | 174.7 | 171.2 | 172.0 | 152.7 | 142.3 |
| Gross profit | 132.8 | 106.8 | 67.4 | 71.9 | 55.5 | 35.6 | 45.4 | 54.1 |
| Gross margin | 23.3% | 26.6% | 24.4% | 29.2% | 24.5% | 17.2% | 22.9% | 27.5% |
| Selling, general and administrative | 122.1 | 77.4 | 48.9 | 42.3 | 40.9 | 41.1 | 45.7 | 38.0 |
| Research and development | 16.0 | 6.0 | 2.6 | 0.4 | 0.9 | 7.9 | 11.1 | 14.5 |
| EBITA | 4.1 | 27.8 | 18.7 | 29.6 | 14.1 | -12.9 | -11.0 | 1.5 |
| EBITA margin | 0.7% | 6.9% | 6.8% | 12.0% | 6.2% | -6.2% | -5.6% | 0.8% |
| Amortization of intangibles | 9.5 | 4.4 | 1.5 | 0.4 | 0.5 | 0.5 | 0.4 | |
| EBIT | -5.4 | 23.4 | 17.1 | 29.2 | 13.7 | -13.4 | -11.4 | 1.5 |
| EBIT margin | -0.9% | 5.8% | 6.2% | 11.8% | 6.0% | -6.4% | -5.8% | 0.8% |
| Pre-tax income | -60.0 | -3.5 | -5.5 | 19.7 | 0.1 | -36.6 | -72.8 | -22.1 |
| Income taxes | 10.2 | -1.2 | -2.2 | 7.9 | 4.4 | -4.3 | -10.0 | -5.4 |
| Tax rate | | 33.7% | 40.1% | 40.3% | 3680.7% | 11.9% | 13.7% | 24.3% |
| Net income | -70.2 | -2.3 | -3.3 | 11.8 | -4.3 | -32.3 | -62.9 | -16.7 |
| Net margin | -12.3% | -0.6% | -1.2% | 4.8% | -1.9% | -15.6% | -31.7% | -8.5% |
| |
| Diluted EPS | ($1.83) | ($0.07) | ($0.10) | $0.37 | ($0.14) | ($1.08) | ($2.05) | ($0.54) |
| Shares outstanding (diluted) | 38.3 | 33.2 | 31.5 | 31.8 | 30.3 | 30.0 | 30.7 | 30.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|